Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

DOI Web Site Web Site PubMed 2 Citations 38 References Open Access
  • Kodera Satoshi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Morita Hiroyuki
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Kiyosue Arihiro
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Ando Jiro
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Takura Tomoyuki
    Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo
  • Komuro Issei
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

Search this article

Abstract

<p>Background: The addition of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to statin therapy reduces the rate of cardiovascular events. This study examined the cost-effectiveness of PCSK9 inhibitor+statin compared with standard therapy (statin monotherapy) in the treatment of triple-vessel coronary artery disease (CAD) in Japan. </p><p>Methods and Results: A Markov model was applied to assess the costs and benefits associated with PCSK9 inhibitor+statin over a projected 30-year period from the perspective of a public healthcare payer in Japan. The incremental cost-effectiveness ratio (ICER), expressed as the quality-adjusted life-years (QALYs), was estimated. The effects on survival and numbers of events were based on the FOURIER trial and the CREDO Kyoto registry. The ICER of PCSK9 inhibitor+statin over standard therapy was 13.5 million (95% confidence interval 7.6–23.5 million) Japanese Yen (JPY) per QALY gained for triple-vessel CAD. The probability of the cost-effectiveness of PCSK9 inhibitor+statin vs. standard therapy was 0.0008% at a cost-effectiveness threshold of 5 million JPY. In patients with poorly controlled familial hypercholesterolemia (FH) with triple-vessel CAD, the ICER was 3.4 million JPY per QALY gained. </p><p>Conclusions: PCSK9 inhibitor plus statin did not show good cost-effectiveness for triple-vessel CAD; however, it showed good cost-effectiveness for patients with triple-vessel CAD and poorly controlled FH in Japan. </p>

Journal

  • Circulation Journal

    Circulation Journal 82 (10), 2602-2608, 2018-09-25

    The Japanese Circulation Society

Citations (2)*help

See more

References(38)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top